Paris, France, June 26th, 2025 - DeepLife, a leader in AI-driven cellular digital twin technology, and Gourmey, a Paris-based cultivated meat pioneer, have partnered to develop the world’s first avian digital twin — a virtual replica of poultry cells engineered to optimize growth conditions, nutrient density, and flavor expression in cultivated meat. The collaboration combines DeepLife’s biology simulation engine with Gourmey’s proprietary cell cultivation platform, accelerating the path toward scalable, cost-effective, and high-quality alternative proteins. Joint research findings have been submitted for publication and are available on BioRxiv.

‍

With cost parity still out of reach for most first-generation cultivated meat systems, technologies like DeepLife’s are emerging as essential tools for second-generation players. By simulating cell behavior under various biological and environmental conditions, DeepLife’s platform enables companies to fine-tune variables such as media composition and metabolic efficiency, before conducting costly wet lab experiments.

‍

“This isn’t just a new biotech innovation - it’s the first step toward a food revolution. And we are delighted to launch this partnership with Gourmey to create the AI-native leader in this emerging market.” - Jonathan Baptista, CEO of DeepLife

‍

Gourmey is one of the few cultivated meat companies with independently validated and viable economics. A 2025 techno-economic assessment conducted by Arthur D. Little confirmed Gourmey’s ability to achieve €7/kg ($3.43/lb) production costs at a commercial 5,000-liter scale — the lowest figure reported to date in any third-party techno-economic model — without reliance on giga-reactors, scaffolds, or pharmaceutical-grade inputs. The integration of DeepLife’s AI enhances this system by modeling cellular responses to environmental inputs across genomics, transcriptomics, and metabolomics layers.

‍

“Integrating DeepLife’s digital twin technology into our platform allows us to model how avian cells respond to different culture conditions before entering the lab. This accelerates our R&D cycles, reduces reliance on costly trial-and-error, and ultimately sharpens our ability to optimize production economics at scale.” — Nicolas Morin-Forest, CEO of Gourmey

‍

‍

The DeepLife-Gourmey collaboration focuses for now on cultivated duck and cultivated poultry products, leveraging DeepLife’s systems biology engine to simulate and enhance key cellular behaviors. With this AI-enabled toolkit, Gourmey’s scientific and engineering team is already running virtual experiments to refine feed formulas, boost protein yield, and tune sensory attributes such as umami intensity and fat structure. These optimizations are actively informing commercial-scale production and supporting regulatory filings underway in Europe, the U.S., and Asia.

‍

Together, DeepLife and Gourmey are laying the groundwork for a new generation of cultivated meat, one that is not only scientifically advanced, but economically viable and ready for real-world impact. As the industry shifts from proof-of-concept to proof-of-scale, this partnership signals a pivotal leap toward bringing smarter, more sustainable proteins to global markets.

‍

About Gourmey

Founded in 2019, Gourmey creates sustainable gourmet products directly from animal cells by combining food innovation with culinary arts. The company comprises a 60-strong international team at its food innovation center in Paris, France. Since its inception, Gourmey has secured over €65 million in public and private investments and is currently preparing for market entry, pending regulatory approvals in several regions. Gourmey focuses on providing new and delicious culinary experiences, with its flagship product set to offer a new choice for foie gras aficionados, chefs, and restaurants globally.

‍

About DeepLife

DeepLife is a techbio company transforming drug development and sustainable biomanufacturing through AI-powered digital twin technology. Backed by $10M Series A funding, DeepLife’s platform enables researchers to develop precise, cost-effective therapies via cellular simulations and multi-omics analytics. Learn more at http://www.deeplife.co.

‍

Read the journal article to discover more about the science behind this collaboration.

‍

Press contacts

Deeplife: media@deeplife.co

Gourmey: press@gourmey.com